Reports Cash, cash equivalents, and marketable securities were $216.9M as of June 30 , compared to $264.4M in cash, cash equivalents, and marketable securities as of December 31, 2023. The company continues to believe that its cash, cash equivalents, and marketable securities will fund its operating expenses and capital expenditures into the second half of 2027..”We continue to apply our proprietary cell-targeted LNP delivery system to develop in vivo genetic medicines for T cells, hematopoietic stem cells and hepatocytes,” said Geoff McDonough, chief executive officer of Generation Bio. “We believe our delivery platform has the potential to create uniquely differentiated in vivo therapeutics that are redosable, delivered at point-of-care, and scalable at low cost, thereby addressing challenges of current ex vivo genetic medicine approaches, creating new market opportunities, and significantly expanding access for patients.” Generation Bio’s novel, proprietary cell-targeted lipid nanoparticle ctLNP delivery system is engineered to have an extended half-life in systemic circulation compared to current LNP technologies that enables the biologic targeting ligands on the company’s ctLNPs to engage with receptors on specific cell types and tissues to achieve selective, potent, and efficient cargo expression. ctLNPs can deliver a variety of cargos, including Generation Bio’s proprietary immune-quiet form of DNA iqDNA . iqDNA is designed to express or replace large genes to achieve years-long expression of therapeutic proteins. Generation Bio is focused on developing a range of differentiated, redosable therapeutics: in vivo T cell therapies for autoimmune indications, in vivo hematopoietic stem cells HSC therapies for sickle cell disease and beta-thalassemia, and systemic delivery to the liver for hemophilia A.